Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.1K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.1K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

230
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
230
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

816
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
816
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

231
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
231
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

158
Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
158
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

186
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
186

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Device-measured physical activity and cardiovascular risk among cardiomyopathy variant carriers in the all of us research program.

American journal of preventive cardiology·2026
Same author

Significant Left Atrial Appendage Leak After LAA Exclusion System Occluded by ASD Closure Device.

JACC. Case reports·2026
Same author

Indiacran: An Intercentre Assessment of Craniofacial Form for Patients With Repaired Complete Unilateral Cleft Lip and Palate.

Orthodontics & craniofacial research·2026
Same author

CD36 Loss-of-Function and Association With Dilated Cardiomyopathy: Insights From the All of Us Research Program.

JACC. Heart failure·2026
Same author

Cardiovascular Health Characterization Using Life's Essential 8 Score in Perimenopausal Women: An Analysis of the National Health and Nutritional Examination Survey.

Journal of the American Heart Association·2026
Same author

Imaging in Cardio-Oncology: Role of Novel Echo Parameters in Breast Cancer and Gynecologic Malignancies.

Current cardiology reports·2026

Related Experiment Video

Updated: Dec 24, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.2K

Strategies to Prevent Cardiotoxicity.

Jason Graffagnino1, Lavanya Kondapalli2, Garima Arora1,3

  • 1Department of Medicine, University of Alabama at Birmingham, 321 Lyons Harrison Research Building, 1720 2nd Ave South, Birmingham, AL, 35294, USA.

Current Treatment Options in Oncology
|April 10, 2020
PubMed
Summary
This summary is machine-generated.

Cardiovascular disease is a major concern for cancer survivors. Pre-treatment cardiovascular assessment is crucial for preventing and mitigating cardiac issues arising from cancer therapies.

Keywords:
Cardio-oncologyCardioprotectionCardiotoxicityChemotherapy-induced cardiotoxicityPharmacotherapy

More Related Videos

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.2K
Zebrafish Larvae as a Model to Evaluate Potential Radiosensitizers or Protectors
04:53

Zebrafish Larvae as a Model to Evaluate Potential Radiosensitizers or Protectors

Published on: August 25, 2022

2.0K

Related Experiment Videos

Last Updated: Dec 24, 2025

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.2K
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
08:09

A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish

Published on: June 7, 2018

10.2K
Zebrafish Larvae as a Model to Evaluate Potential Radiosensitizers or Protectors
04:53

Zebrafish Larvae as a Model to Evaluate Potential Radiosensitizers or Protectors

Published on: August 25, 2022

2.0K

Area of Science:

  • Cardio-oncology
  • Cardiovascular disease in cancer survivors
  • Cancer therapy cardiotoxicity

Background:

  • Cardiovascular disease (CVD) is a leading cause of mortality in cancer survivors.
  • Current cardio-oncology research relies on limited clinical trials with heterogeneous patient groups.
  • Oncology trials often exclude patients with pre-existing cardiovascular conditions, underrepresenting real-world risks.

Purpose of the Study:

  • To highlight the limitations in current cardio-oncology research and clinical trial design.
  • To emphasize the need for comprehensive cardiovascular assessment before cancer treatment.
  • To advocate for a shift towards proactive prevention of cardiotoxicity in cancer patients.

Main Methods:

  • Review of existing clinical trial methodologies and data in cardio-oncology.
  • Analysis of the impact of cancer therapies on cardiovascular health.
  • Discussion of historical data from anthracycline use and its implications for future research.

Main Results:

  • Cardiovascular toxicity signals from cancer therapies are often detected late (Phase IV studies), necessitating mitigation rather than prevention.
  • Existing oncology trials frequently fail to capture the full spectrum of cardiovascular events due to patient selection and varied definitions.
  • Decades of experience with anthracyclines provide a foundation, but new cancer therapies require dedicated cardiovascular research.

Conclusions:

  • Proactive cardiovascular risk assessment prior to cancer therapy is essential for optimizing patient outcomes.
  • There is an urgent need to move beyond anthracycline-focused research to address the cardiovascular side effects of all cancer treatments.
  • Integrating cardiovascular care into oncology is imperative for improving long-term survival and quality of life for cancer survivors.